Build your base

Alienum phaedrum torquatos nec eu, vis detraxit periculis ex, nihil expetendis in mei. Mei an pericula euripidis, hinc partem ei est.

Archive

Begonya is Patient Engagement in Research Coordinator at Sant Joan de Déu Chidren’s Hospital (Spain). She has long experience in the field of the involvement of patients and families in research initiatives. She has also a personal story as a caregiver and patient advocate because is the sister of a young adult with cerebral palsy. Her areas of expertise are focused in paediatric patients involvement in research and specifically in the field of clinical trials. Other relevant background of her profile is: Fellow of EUPATI (first cohort), Coordinator of eYPAGnet (European Young Patients Advisory Group Network – www.eypagnet.eu); Coordinator of Kids Barcelona (YPAG of Sant Joan de Déu Children’s Hospital- www.kidsbarcelona.org); member of Children’s Medicines Working Party of EFPGCP; volunteer member of...

Dr. Gruber is the Chief of Pediatric Hematology Oncology Stem Cell Transplant and Regenerative Medicine at Stanford University where she also serves as the Director of the Bass Center for Childhood Cancer and the Associate Director for Childhood Cancer at the Stanford Cancer Institute. Dr. Gruber is a physician scientist that actively engages in both laboratory and clinical research, with a focus on high risk pediatric leukemia. She has developed and activated several multi-institutional therapeutic trials in pediatric leukemia that span newly diagnosed and relapsed disease including a treatment protocol for newly diagnosed infants with acute lymphoblastic leukemia (NCT02553460). ...

Senior Vice President of Clinical and Scientific Development at the Institute for Advanced Clinical Trials for Children and Clinical Associate Professor University of Texas at Austin....

Dominik received his medical degree and MD in paediatric drug development from the University Erlangen/ Nuremberg (Germany) in 2007. He held a training post in Germany in paediatric haematology/ oncology (University Hospital Muenster) and worked in Germany and the UK (Royal Marsden Hospital/ Institute of Cancer Research UK) in paediatric oncology and paediatric oncology drug development. In 2014 he joined the UKs medicines regulatory agency (MHRA) with positions in the Licensing and Post-marketing Division as accredited assessor and national expert to the European Medicines Agency (EMA), before joining the EMAs Paediatric Medicines Office in 2018 as scientific office. Dominik is involved in product and regulatory science related aspects concerning paediatric oncology drug development. In this capacity he is also the...

Since 2002, Dr. Karen Yeo has led projects relating to the extrapolation of in vitro data to predict in vivo pharmacokinetics in humans. This has included development and implementation of the models into the Simcyp Simulator.  Her specific research interests include physiologically based pharmacokinetic modeling and prediction of drug-drug interactions.  She received her BSc Honours degree in Physics at the University of Natal in South Africa in 1989 and her PhD in Drug Metabolism from the University of Sheffield in 1995. This was followed by a two-year position as a Postdoctoral Leukaemia Research Fund Fellow in the area of Childhood Acute Lymphoblastoid Leukaemia. Prior to joining Simcyp in 2002, Karen held a 5-year lectureship in the Department of Clinical Pharmacology & Therapeutics at...

Max Williamson was diagnosed with testicular cancer aged 15. Now in remission, Max now works in patient advocacy across Europe, primarily in research across children's and young people's cancer. His main areas of focus are on equitable access to clinical trials and advocacy, as well as on late effects of cancer treatments....

Dr. John van den Anker is a Professor of Pediatrics, Pharmacology, Physiology, Genomics and Precision Medicine at the George Washington University School of Medicine and Health Sciences, Washington, DC and holds the Evan and Cindy Jones Endowed Chair in Pediatric Clinical Pharmacology. He also is the Eckenstein-Geigy Distinguished Professor of Pediatric Pharmacology at the University Children’s Hospital of Basel, University of Basel, Switzerland....

Mark Turner is Professor of Neonatology and Research Delivery at the University of Liverpool, UK. He graduated from Manchester University with a medical degree in 1991 and a PhD in 1999 (placental physiology). He trained in neonatal medicine in the North West of England and has worked as a Consultant Neonatologist in Liverpool since 2005. His research aims to improve the access of newborn babies and children to high quality medicines. This has included studies of dosing, safety, and efficacy of 15 medicines (contributing to writing 5 paediatric investigation plans); excipient kinetics; manipulations of medicines; the assessment of adverse drug reactions; and the value of age-appropriate formulations. He believes that the coherent integration of the design and conduct of clinical trials is...

With more than 20 years of global drug development experience, Dr. Patrick Smith works across all phases of development with particular expertise in infectious diseases, oncology, and inflammation as well as novel early development program design and applying modeling and simulation to solve critical development problems. Patrick has over 125 peer-reviewed publications in journals, including NEJM and Lancet....

Mark Shapiro is the principal investigator for XCELSIOR and BEAT19, two patient-powered real-world data and outcomes registries in cancer and COVID-19, respectively. For two decades he was driven growth and innovation programs in clinical research. Prior to joining xCures, Mr. Shapiro was SVP, Operations at a global CRO, where he was responsible for a team of about 500 drug development professionals in 30 countries, and a portfolio of more than 100 active clinical trials. He was previously a management consultant in the Clinical Development and Medical Affairs consulting practice at Campbell Alliance, now part of Syneos Health Consulting. He also managed a pediatric clinical trials network coordinating center at Duke University focused on clinical, pharmacogenomic, and psychometric research. He has...